Novavax (NASDAQ:NVAX) Downgraded by Zacks Research to “Hold”

Zacks Research cut shares of Novavax (NASDAQ:NVAX) from a strong-buy rating to a hold rating in a research note issued to investors on Thursday,Zacks.com reports.

A number of other analysts have also issued reports on the company. Weiss Ratings restated a “sell (d)” rating on shares of Novavax in a report on Tuesday. TD Cowen upped their price target on Novavax from $8.00 to $9.00 and gave the company a “hold” rating in a research report on Wednesday, May 6th. B. Riley Financial reissued a “buy” rating on shares of Novavax in a research note on Thursday, April 9th. Wall Street Zen downgraded Novavax from a “hold” rating to a “sell” rating in a research note on Saturday, August 1st. Finally, BTIG Research restated a “buy” rating and set a $19.00 price objective on shares of Novavax in a research report on Thursday, June 11th. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, Novavax has a consensus rating of “Hold” and an average price target of $13.00.

Novavax Stock Performance

Shares of NASDAQ:NVAX opened at $7.95 on Thursday. The company has a market cap of $1.31 billion, a PE ratio of -5.23 and a beta of 2.46. Novavax has a 52 week low of $6.20 and a 52 week high of $11.97. The firm has a 50 day simple moving average of $8.72 and a 200 day simple moving average of $8.97.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.06. Novavax had a negative net margin of 59.87% and a negative return on equity of 14.82%. The firm had revenue of $56.70 million during the quarter, compared to analyst estimates of $52.51 million. During the same quarter last year, the business posted $0.62 EPS. The company’s revenue was down 76.2% on a year-over-year basis. On average, equities analysts predict that Novavax will post -0.31 earnings per share for the current year.

Institutional Trading of Novavax

Several hedge funds and other institutional investors have recently modified their holdings of NVAX. Flagship Harbor Advisors LLC acquired a new position in Novavax in the 4th quarter worth about $33,000. Quarry LP acquired a new stake in shares of Novavax during the 3rd quarter valued at about $33,000. Duncker Streett & Co. Inc. lifted its holdings in shares of Novavax by 917.3% during the 1st quarter. Duncker Streett & Co. Inc. now owns 4,242 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 3,825 shares during the last quarter. KBC Group NV grew its stake in shares of Novavax by 34.9% in the 1st quarter. KBC Group NV now owns 4,746 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 1,229 shares in the last quarter. Finally, State of Wyoming bought a new stake in shares of Novavax in the 2nd quarter valued at approximately $52,000. 53.04% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Novavax

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Novavax reported a second-quarter adjusted loss of $0.32 per share, better than the expected $0.38 loss, while revenue of $56.7 million exceeded estimates of approximately $52.5 million. NVAX Q2 Earnings & Sales Beat Estimates, 2026 Sales Outlook Raised
• Positive Sentiment: The company raised its full-year 2026 adjusted revenue framework to $235 million-$275 million from $230 million-$270 million and reduced combined GAAP research and development and selling, general and administrative expense guidance by $10 million at the midpoint. Novavax Raises 2026 Outlook After Q2 Beat
• Positive Sentiment: Novavax said completion of its manufacturing technology transfer to Sanofi is expected in mid-2027, potentially triggering a $75 million milestone payment. Sanofi also plans to advance discussions with regulators regarding timing for its Phase 3 COVID-19 and influenza combination-vaccine trial. Novavax Lifts Annual Revenue Forecast
• Neutral Sentiment: Novavax ended June with approximately $724 million in cash, cash equivalents, marketable securities and restricted cash. It also highlighted partner-led Matrix-M projects and plans to move its C. difficile vaccine program into clinical development as early as 2027. Novavax Reports Second Quarter 2026 Financial Results
• Negative Sentiment: Revenue fell approximately 76% from the prior-year quarter to $56.7 million, product sales were only $19 million, and Novavax posted a $53 million net loss versus $107 million of net income a year earlier. The results underscore the company’s dependence on licensing revenue and milestone payments as vaccine demand wanes. Novavax Q2 Revenue Falls 76 Percent

Novavax Company Profile

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.